Hepatitis Be Antigen
The HBe assay is intended for use as an aid in the diagnosis of patients with hepatitis B viral infections, when used in conjunction with results from other HBV marker assays.
HBeAg appears in acute B hepatitis with or shortly after HBsAg, when the patient is most infectious. HBeAg is found only in HBsAg-positive sera. During the HBeAg-positive state, usually three to six weeks, hepatitis B patients are at increased risk of transmitting the virus to their contacts, including babies born during this period. Exposure to serum or body fluid positive for HBeAg and HBsAg is associated with three to five times greater risk of infectivity than when HBsAg positivity occurs alone. Persistence of HBeAg is associated with chronic liver disease.
Serum or plasma
0.6 mL (Note: This volume does not allow for repeat testing.)
Gel-barrier tube or lavender-top (EDTA) tube
This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R). It is recommended to ask all patients who may be indicated for this test about biotin supplementation. Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.
If tube other than a gel-barrier tube is used, transfer separated serum or plasma to a plastic transport tube.
Refrigerate: Samples can be stored at 2°C to 8°C for seven days or at -20°C for one year.
Stable for three freeze/thaw cycles.
Non-EDTA plasma specimen; heat-inactivated specimens; cord blood; cadaver specimens; or body fluids other than serum or EDTA plasma